Abstract
In animal models, ezetimibe has been observed to lower plasma total, chylomicron, very-low density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol levels.
It inhibits the development of atherosclerosis in ApoE knockout mice. In combination with statins in dogs, it reduces plasma cholesterol in a synergistic manner.
In a study in humans, treatment with ezetimibe gave a 54% reduction in absorption of cholesterol. There was a wide range of cholesterol absorption and drug activity among these individuals.
Get full access to this article
View all access options for this article.